Knight Therapeutics, Inc. (GUD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioSyent, Inc.

Knight Therapeutics, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Fennec Pharmaceuticals, Inc.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Arch Biopartners, Inc.

Defence Therapeutics Inc

Cybin, Inc.

Mindset Pharma, Inc.

Why is Knight Therapeutics, Inc. ?

With a fall in PBT of -809.79%, the company declared Very Negative results in Jun 25

INTEREST(Q) At CAD 2.37 MM has Grown at 35.19%
RAW MATERIAL COST(Y) Grown by 15.29% (YoY)
CASH AND EQV(HY) Lowest at CAD 232.7 MM

Underperformed the market in the last 1 year

The stock has generated a return of 3.05% in the last 1 year, much lower than market (S&P/TSX 60) returns of 22.54%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Knight Therapeutics, Inc. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Knight Therapeutics, Inc.

3.55%

0.18

26.07%

S&P/TSX 60

23.72%

1.54

14.62%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

17.91%

EBIT Growth (5y)

-10.89%

EBIT to Interest (avg)

-1.52

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

0.42

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.15%

ROCE (avg)

0.11%

ROE (avg)

1.02%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.79

EV to EBIT

-52.75

EV to EBITDA

13.83

EV to Capital Employed

0.79

EV to Sales

1.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-1.49%

ROE (Latest)

-0.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 44.79 MM

PRE-TAX PROFIT(Q)

At CAD 2.67 MM has Grown at 268.55%

NET PROFIT(Q)

At CAD 0.8 MM has Grown at 472.13%

DEBTORS TURNOVER RATIO(HY)

Highest at 3.55 times

NET SALES(Q)

Highest at CAD 121.55 MM

OPERATING PROFIT(Q)

Highest at CAD 18.41 MM

-13What is not working for the Company

NET PROFIT(HY)

At CAD -6.09 MM has Grown at -85.92%

INTEREST(HY)

At CAD 4.74 MM has Grown at 12.93%

RAW MATERIAL COST(Y)

Grown by 9.73% (YoY

CASH AND EQV(HY)

Lowest at CAD 186.75 MM

DEBT-EQUITY RATIO (HY)

Highest at 1.39 %

Here's what is working for Knight Therapeutics, Inc.

Pre-Tax Profit

At CAD 2.67 MM has Grown at 268.55%

over average net sales of the previous four periods of CAD -1.59 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 0.8 MM has Grown at 472.13%

over average net sales of the previous four periods of CAD -0.21 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Operating Cash Flow

Highest at CAD 44.79 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Net Sales

Highest at CAD 121.55 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Net Sales

At CAD 121.55 MM has Grown at 26.43%

over average net sales of the previous four periods of CAD 96.14 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD 18.41 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Debtors Turnover Ratio

Highest at 3.55 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at CAD 17.77 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (CAD MM)

Depreciation

At CAD 17.77 MM has Grown at 46.38%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (CAD MM)

Here's what is not working for Knight Therapeutics, Inc.

Interest

At CAD 4.74 MM has Grown at 12.93%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Cash and Eqv

Lowest at CAD 186.75 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 1.39 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 9.73% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales